After his time at CHA, Brian studied at Northeastern University and worked at Acceleron Pharma for nine years. In 2016, he joined Finch Therapeutics' founding team and launched a microbiome biotech. Brian has successfully supported the growth of the company from 10 to 150 employees through strategic partnerships and fundraising activities. The microbiome field is in its infancy; however, it is gaining traction and focus from investors and large pharma companies alike. They (and many others) have been working to blaze a path in an otherwise uncharted therapeutic landscape and see broad application to modulate many unmet disease indications through the microbiome and gut bacteria.